CSIMarket
 
Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
 
 
Price: $0.3000 $0.02 6.082%
Day's High: $0.32 Week Perf: 38.57 %
Day's Low: $ 0.28 30 Day Perf: 11.11 %
Volume (M): 309 52 Wk High: $ 0.81
Volume (M$): $ 93 52 Wk Avg: $0.42
Open: $0.29 52 Wk Low: $0.18



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 37
 Employees 51
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Frequency Therapeutics Inc
Frequency Therapeutics Inc. is a biotechnology company based in Woburn, Massachusetts, that is focused on developing novel therapies for hearing loss and communication disorders. The company was founded in 2015 by leading experts in regenerative biology and inner ear biology, including Christopher Loose, Robert Langer, and Will McLean. Frequency Therapeutics is currently at the forefront of research into regenerating sensory hair cells in the inner ear, a breakthrough that could revolutionize the treatment of hearing loss.

The company's lead product candidate, FX-322, is a proprietary combination of small molecules designed to activate progenitor cells to differentiate into hair cells in the inner ear. FX-322 is administered via an injection into the middle ear and has the potential to restore hearing loss caused by damage to the hair cells in the inner ear. The clinical trials conducted by Frequency Therapeutics have shown promising results, including improvements in natural hearing ability, increased word recognition, and improvements in speech-in-noise scores.

In addition to FX-322, Frequency Therapeutics is also developing additional therapies for hearing loss and communication disorders. These include FX-701, a drug that targets the STAT3 signaling pathway to promote the differentiation of endogenous progenitor cells into cochlear supporting cells, and a gene therapy that is currently in preclinical development to target hearing loss caused by mutations in specific genes.

Frequency Therapeutics has a strong emphasis on advancing its products through rigorous clinical trials, including randomized, double-blind, placebo-controlled studies. The company has a team of experienced professionals dedicated to researching and developing novel therapies for hearing loss and communication disorders. The company has also received significant funding from leading venture capital firms, including Polaris Partners, Morningside Venture Investments, and Longitude Capital.

Overall, with its cutting-edge technology and a strong focus on research and development, Frequency Therapeutics has the potential to make a significant impact in the field of hearing loss and communication disorders. The company is poised to transform the way these conditions are treated and improve the quality of life for millions of people around the world.


   Company Address: 75 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 315-4600   Stock Exchange / Ticker: NASDAQ FREQ
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Frequency Therapeutics Inc

Frequency Therapeutics Inc Shines Amidst Third Quarter Results, Generating Excitement in Major Pharmaceutical Preparations Sector

The stock market is buzzing with excitement as companies across various sectors release their earnings for the fiscal July to September 30, 2023 period. One particular sector that deserves attention is Major Pharmaceutical Preparations, as multiple entities within this industry have announced their earnings. Among them, Frequency Therapeutics Inc has caught the spotlight with its operating shortfall of $-12.665 million.
What sets Frequency Therapeutics Inc apart is its commitment to innovation and progress. The managing day to day operations have taken an impressive turn, surpassing the performance of the same category in the comparable time-frame of the previous year. This growth trajectory is especially significant for a company that operates primarily in the progress span.

Frequency Therapeutics Inc

Frequency Therapeutics Inc. Reports Significant Progress as Operating Shortfall Narrows to $-21.273 Million in Fiscal Q2 2023


Introduction
Frequency Therapeutics Inc, the innovative biotechnology company specializing in regenerative medicine, recently released its financial results for the April to June 2023 earnings cycle. Although there were concerns about the company's operating shortfall, it is worth noting that Frequency Therapeutics has successfully implemented strategies to trim losses and improve cost-effectiveness. This bullish trend demonstrates the company's potential for growth and profitability in the coming years.
Trimming Losses and Improving Cost-effectiveness
During the fiscal interval ending June 30, 2023, Frequency Therapeutics Inc reported an operating shortfall of $-11.831 million, a noticeable improvement from the previous year's figure of $-21.273 million. This reduction of approximately 44% in operating shortfall is an impressive feat for a company still in its growth phase. It showcases Frequency Therapeutics' commitment to refining its business strategy and retaining a sharp focus on cost control measures.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com